The Alliance for Regenerative Medicine Releases Agenda for Third Annual Regen Med Investor Day

Share Article

32 company presentations and five expert-led sessions will cover the future outlook for the industry, commercialization and market access strategies, capital markets, gene therapy delivery and anticipated clinical and commercial milestones for T-cell therapies

News Image

The Alliance for Regenerative Medicine (ARM) today revealed its complete agenda for its upcoming third annual Regen Med Investor Day, taking place next Wednesday, March 25, 2015, in New York City. This event, held in partnership with Piper Jaffray and supporting bank Maxim, is a full-day conference expected to attract 350 attendees, including investors, members of the media and leading company executives.

This year’s event includes 32 company presentations and five expert-led sessions that will cover the future outlook for the industry, commercialization and market access strategies, capital markets, gene therapy delivery and anticipated clinical and commercial milestones for T-cell therapies.

“Investors are recognizing that our industry holds the key to the next-generation of transformational medical advances,” said Edward Lanphier, ARM Chairman and President and CEO of Sangamo BioSciences. “Advanced therapies, including regenerative medicines, gene therapy and modified cell therapies, have the capacity to create safe and effective treatments and potentially cures for patients around the world.”

2015 Panel Sessions and Speakers:

Fireside Chat: The Future Outlook for Advanced Therapies
Edward Tenthoff, Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Malcolm Brenner, M.D., Ph.D., Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital; Professor, Baylor College of Medicine
Olivier Danos, Ph.D., SVP, Gene Therapy, Biogen Idec

Market Access Strategies for Advanced Therapies
Jason Kolbert, Senior Managing Director, Maxim Group (moderator)
Brian Abraham, Senior Director, Market Access & Reimbursement, Nuo Therapeutics
John Doyle, Dr.P.H., SVP & Managing Director, Advisory Services, Quintiles
Michael Werner, Executive Director, Alliance for Regenerative Medicine; Partner, Holland & Knight

Fireside Chat: Capital Markets & Attracting Institutional Interest
C. Randal Mills, Ph.D. President & CEO, California Institute for Regenerative Medicine (introductory remarks)
James Douglas, Managing Director, Healthcare Investment Banking, Piper Jaffray (moderator)
Carl Gordon, Ph.D., Founding Partner & Co-Head of Global Private Equity, OrbiMed
Anthony Sun, M.D., Partner, Aisling Capital

Gene Therapy Delivery: What Can Be Accomplished with Existing Vector Technology & How Should We Expect It To Evolve?
Joshua Schimmer, M.D., Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
David Kirn, M.D., CEO & Co-Founder, 4D Molecular Therapeutics
Richard Lawn, Ph.D., Consulting Professor, Cardiovascular Institute, Stanford University; Consulting Scientist, Cardiogen Sciences
Ken Mills, President & CEO, REGENXBIO
Steven Paul, M.D., CEO, Voyager Therapeutics

Adoptive T-Cell Therapies: Considering Key Upcoming Clinical & Commercial Milestones
Joshua Schimmer, M.D., Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Douglas Doerfler, President & CEO, MaxCyte
Thomas Farrell, President & CEO, Bellicum Therapeutics
Peter Ho, Ph.D., Director, Business Development, Lion Biotechnologies
Rick Morgan, Ph.D., VP, Immunotherapy, bluebird bio

2015 Presenting Companies:
AGTC, Argos Therapeutics, Asterias Biotherapeutics, Audentes Therapeutics, Avalanche Biotechnologies, bluebird bio, Bone Therapeutics, BrainStorm Cell Therapeutics, Capricor Therapeutics, Cardio3 BioSciences, Cellular Biomedicine Group, Cellular Dynamics International, Cesca Therapeutics, Fate Therapeutics, Fibrocell Science, Histogenics, Inovio Pharmaceuticals, Juventas Therapeutics, MaxCyte, MiMedx, NeoStem, Osiris Therapeutics, Oxford BioMedica, Pluristem Therapeutics, Regeneus, ReNeuron, Sangamo BioSciences, TiGenix, TxCell, Vericel, ViaCyte, Voyager Therapeutics

This event is held in partnership with Piper Jaffray and supporting bank Maxim Group. Industry sponsors include California Institute for Regenerative Medicine (CIRM), Cryoport, CTI Clinical Trial & Consulting Services, Kawasaki Heavy Industries, Lonza, NeoStem, PCG Advisory Group, Progenitor Cell Therapy (PCT) and TrakCel. Additional event supporters include Edison and The Life Sciences Report. The event will be held March 25, 2015, beginning at 7:30am at the Metropolitan Club at One East 60th Street in New York City.

For more information, please visit the event’s website at http://www.arminvestorday.com. Credentialed investors and life science strategic partners can indicate their interest in attending here: https://alliancerm.wufoo.com/forms/interested-in-attending-s1dlq2vs0yzpcya/. Members of the media interested in attending should contact Lyndsey Scull at lscull(at)alliancerm(dot)org.

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Michelle Linn
Linnden Communications
+1 (774) 696-3803
Email >